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ABSTRACT
Acetylcholinesterase (AChE) activity is found in abundance in reticulocytes and neurons and was
developed as a marker of reticulocyte EVs in the 1970s. Easily, quickly, and cheaply assayed, AChE
activity has more recently been proposed as a generic marker for small extracellular vesicles (sEV) or
exosomes, and as a negative marker of HIV-1 virions. To evaluate these proposed uses of AChE activity,
we examined data from different EV and virus isolation methods using T-lymphocytic (H9, PM1 and
Jurkat) and promonocytic (U937) cell lines grown in culture conditions that differed by serum content.
When EVs were isolated by differential ultracentrifugation, no correlation between AChE activity and
particle count was observed. AChE activity was detected in non-conditionedmediumwhen serum was
added, andmost of this activity resided in soluble fractions and could not be pelleted by centrifugation.
The serum-derived pelletable AChE protein was not completely eliminated from culture medium by
overnight ultracentrifugation; however, a serum “extra-depletion” protocol, in which a portion of the
supernatant was left undisturbed during harvesting, achieved near-complete depletion. In conditioned
medium also, only small percentages of AChE activity could be pelleted together with particles.
Furthermore, no consistent enrichment of AChE activity in sEV fractions was observed. Little if any
AChE activity is produced by the cells we examined, and this activity was mainly present in non-
vesicular structures, as shown by electron microscopy. Size-exclusion chromatography and iodixanol
gradient separation showed that AChE activity overlaps only minimally with EV-enriched fractions.
AChE activity likely betrays exposure to blood products and not EV abundance, echoing theMISEV 2014
and 2018 guidelines and other publications. Additional experiments may be merited to validate these
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Extracellular vesicles (EVs) function in intercellular com-
munication and are considered an attractive component of
the “liquid biopsy” in part because EV molecular markers
may identify parental cells [1–3]. EVs and subset popula-
tions are variously defined by biogenesis, size and density,
morphology, protein markers, and combinations thereof
[4]. A wealth of molecules, especially proteins, have been
proposed as markers of EVs or EV subsets, but heteroge-
neity and technical biases of different isolation protocols
present challenges to defining a single generic marker of
EVs from multiple sources [5–7]. The MISEV 2014 and
2018 minimal information guidelines of the International
Society for Extracellular Vesicles (ISEV) [8,9] recommend
characterization of multiple EV markers (i.e. tetraspanins,
cytosolic ESCRTs, Rabs) as well as absence of putatively
EV-depleted markers (i.e. calnexin, GM130, cytochrome
C) before assigning functions to EVs in biological systems.
Caution is also urgedwhen using extracellular proteins that
have been historically associatedwith EVs but thatmay not
be universal markers.
One such extracellular protein is acetylcholinester-
ase (AChE). AChE is produced in abundance by neu-
rons and red blood cells (RBCs). In vertebrates, two
cholinesterases (ChEs), AChE and butyrylcholinester-
ase (BChE), hydrolyse the neurotransmitter acetylcho-
line (ACh) into acetic acid and choline [10–13].
Different ChE forms arise from alternative splicing
events and multimerization (G4, G2 and G1), with
different tissue specificity and isoform abundance
across species [11,13–15]. G4 AChE-S (S for
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“synaptic”) is soluble, while G2 AChE-E (E for “ery-
throcyte”) is anchored in the external leaflet of the
erythrocyte membrane by glycosylphosphatidylinositol
(GPI). Soluble and anchored forms of AChE as well as
relative abundance of AChE and BChE may vary in the
serum of different species [10,15–19].
EVs produced by reticulocytes during maturation
towards erythrocytes, and by drug-treated erythrocytes,
were studied intensively beginning in the 1970s [20–27],
and AChE activity was among the regularly studied char-
acteristics of these membranes. EVs were typically charac-
terized by known reticulocyte and erythrocyte phenotype
in relation tomembrane- and cytosolic enzymes, including
the lipid-anchored AChE-E [12,14]; lipid analysis by con-
ventional biochemistry; and morphology, as assessed by
electron microscopy [22,24,26,27]. Higher AChE-E
enzyme activity (normalized by total protein) was reported
for “nanovesicles” pelleted at 100,000 x g compared with
microvesicles pelleted at 16,000 x g or bulk plasma mem-
brane [24,26]. In these studies, vesicle release was in some
cases induced biochemically; elsewhere, EV release was
associated with reticulocyte maturation and erythrocyte
aging [22,24], consistent with other reports [12]. Thus, by
the late 1970s, AChEwas well validated as amarker of RBC
EVs, and was used as such in the 1980s [22,24] as well as in
later work on reticulocytes and erythroleukemia [28–30].
Interestingly, though, AChE is now sometimes used as a
generic marker of EVs or of late endosome-origin “exo-
somes” [31–34], including in commercial quantitation kits.
This, despite the unclear relevance of many of the cells
under investigation to neuronal or erythrocyte systems.
Furthermore, AChE is presumably found in the serum
commonly used in cell cultures and may thus be
exogenous.
To evaluate the tenability of AChE activity as a generic
EV marker, we tested AChE activity in materials gathered
using multiple isolation methods from multiple cell lines
and sources, under cell culture conditions varying by the
presence of serum, and in two different laboratories. We
conclude that, except possibly in systems with high AChE
activity such as reticulocytes or neurons, AChE is unlikely
to be useful as a generic EV marker, since it is mostly
present in structures other than EVs. Furthermore, an
apparent association of AChE with EVs can be a technical
artefact of serum-containing cell culture or isolation from
biological sources.
Results
Reasoning that an extremely robust association between
AChE and extracellular particle counts might be noticeable
even across experiments and systems, we first searched for
an overall correlation between particle counts and AChE
activity compiled from numerous experiments (n = 37)
involving EVs from culturemedium in which both particle
counts and AChE activity had been measured. No signifi-
cant association betweenAChE activity and particle counts
was observed (Supplemental Figure 1). However, numer-
ous factors might obscure a real relationship between
AChE and EVs when data from multiple experiments are
assessed together. These factors range from different
sources of serum and different cell types to time-, setting-,
and operator-dependent variability of AChE activity assays
or nanoparticle tracking analyses (NTA). Therefore, we
examined the correlation of particle count and AChE
activity across similar experiments or within the same
experiment. For all experiments, no significant correlation
of AChE activity and particle counts was observed. To
provide a few examples, this was the case for 100,000 x g
(100 K) pellets from serum-free culture of H9 cells
(Figure 1(a,b)).Measuring particle count with NTA instru-
ments from different manufacturers did not affect results
(Figure 1(a,b)): particle counts by NanoSight NS500 and
ParticleMetrix Zeta View, respectively). Fractions from the
U937 promonocytic line also showed no association of
particle count with AChE activity (Figure 1(c)).
Limited AChE activity is recovered by pelleting
unconditioned media
Serum-freemedia (AIMVandRPMI) and serum-contain-
ing medium (10% FBS in RPMI = R10) were processed
(180 mL each) by differential centrifugation to determine
the presence of AChE activity in differentially centrifuged
pellets of non-conditioned medium (NCM) as well as
unprocessed (whole) NCM. No AChE activity was
detected in either of the two serum-free non-conditioned
media or, as would be expected, in centrifuge pellets
obtained from NCM at increasing centrifugation speeds
(Figure 2(a)). In contrast, high levels of AChE activity were
found in serum-containing NCM (Figure 2(a)). Only a
small percentage of this activity (approximately 1% total
in these experiments) could be recovered from pellets
obtained by successively higher-speed centrifugations
(Figure 2(a)). Here, slightly more AChE activity was recov-
ered from the 100 K pellet than from the 2,000 x g (2 K)
and 10,000 x g (10 K) pellets, although this difference may
be serum batch- or experiment-dependent.
Limited AChE activity is recovered by pelleting
from serum-replete or serum-free cell culture
conditioned media
To assess the ability of cultured cells to release AChE,
culture conditioned media (CCM) were prepared with
T-lymphocytic line PM1 grown and maintained in 10%
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FBS medium (R10) or switched to serum-free medium
(AIM V). CCM was fractionated by differential ultra-
centrifugation as before. A small amount of AChE
activity was detected in sequential centrifugation
pellets, and more activity was generally but not always
recovered in the 100 K pellet than in the lower-speed
pellets (Figure 2(b)). From cultures switched to serum-
free medium, some AChE activity was detected in the
pelleted material, although about 10 times less than
from cells cultured in serum-replete medium, and
AChE activity was on average lower in the 100 K pellet
than in others (Figure 2(b)).
In comparison with particle counts, AChE activity is
relatively unaffected by conditioning and
centrifugation
Examining the data in a different way, we reasoned
that, if AChE were a generic marker of EVs, AChE
activity should be higher on a per-particle basis in EV-
enriched compared with supernatant fractions. We
thus followed AChE activity and particle counts from
NCM to CCM and through successive centrifugation
steps in both pellet and supernatant (see experimental
scheme in Figure 3(a)). H9 cells were used to condition
the serum-containing (R10) medium. For serum-con-
taining medium, total AChE units were within the
range measured across all experiments reported herein
(from approximately 1–4 × 105 mU/180 mL NCM and
CCM). Across experiments, total levels of AChE were
not strongly affected by conditioning, nor did succes-
sive rounds of centrifugation (2 K, 10 K, 100 K) result
in substantial depletion of AChE from supernatants
(Figure 3(b)). Although inconsistent reduction in
AChE activity in supernatants was observed in several
experiments (up to an apparent 40% in one experi-
ment), examining the pellets, recovered AChE was
insufficient to explain these reductions (Figure 3(c)).
Summing the activity in all pellets for each experiment,
total AChE recovery averaged only 1.8% (1.4%-2.3%)
of the amount in CCM. In contrast with AChE activity,
particle counts were increased by conditioning by 2–5
fold in 3 of 5 experiments (but not in another 2, Figure
3(d)). Successive centrifugation resulted in depletion of
particles from the supernatant (Figure 3(d)), such that
100 K supernatant consistently had particle levels at or
below those of NCM. These particles were recovered in
pellets (Figure 3(e)). Adding together the particle
counts from 2 K, 10 K, and 100 K pellets and compar-
ing with the particle count in each CCM, the total
percentage of pelleted particles averaged 54.1%
(range: 17.6%-93.3%). Thus, AChE activity was neither
added by conditioning nor depleted by centrifugation
to the same extent as particles. AChE activity normal-
ized per particle was up to 100 times lower in any given
Figure 1. Acetylcholinesterase activity and particle counts do
not correlate. (a) AChE activity (measured within 4 hr after
separation) and particle counts of 100 K pelleted EVs from H9
cells measured by (a) NanoSight NS500 (camera setting 12) or
(b) ParticleMetrix ZetaView (JHU settings, see Materials and
Methods). (c) AChE activity and particle counts of EVs from
U937 cells (ZetaView, JHU settings).
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pellet as compared with its corresponding supernatant
(Figure 3(f)). Across experiments, the pellet: superna-
tant ratio of activity/particle was low, and significantly
lower for 100 K than for 2 K samples (Figure 3(g)).
In serum-free conditions (AIM V), AChE activity
was below the limit of quantitation of our assay in all
fractions of supernatant and all pellets except for the 10
K pellet (which was around the limit of quantitation).
In contrast, particle addition and depletion by condi-
tioning and ultracentrifugation was consistent with the
results above (Supplemental Figure 2). Conditioning
increased particle number by approximately fourfold,
and centrifugation reduced particles 10-fold. 60.5% of
particles were recovered in the centrifuge pellets.
Bovine AChE protein and non-vesicle-associated
AChE are co-isolated with cell-derived, mostly
AChE-negative EVs
We next used Western blotting (WB) to determine the
presence of AChE in EV-containing pellets, regardless of
its enzymatic activity. For these experiments, another T
lymphocytic cell line (Jurkat) was cultured in serum-free
(TexMACS, Miltenyi) or serum-containing (10% FBS)
RPMI medium, and the medium was processed by differ-
ential ultracentrifugation as above. The full-length protein
was readily detected in the 2 K and 100 K pellets recovered
from 20 ml of 10% FBS-medium, both non-conditioned
(NCM) and conditioned for 48 h by 20million cells (CCM,
Figure 4(a)). By contrast, when analysing TexMACS med-
ium, we detected AChE mainly in the 2 K pellets of CCM
(occasionally in the 100 K), and not inNCMpellets (Figure
4(b)). Since EVs are present in FBS, a recommended
practice to isolate EVs released by cultured cells without
contamination by FBS-derived EVs is to pre-deplete FBS-
containing medium of EVs by overnight ultracentrifuga-
tion [35–37]. 2 K pellets from EV-depleted serum-contain-
ing NCM still contained AChE, whereas the 100 K pellets
did not (Figure 4(c)). However, when taking extra care to
recover only “extra-depletedmedium”– bypipetting super-
natant from the top down and leaving 10%ofmediumover
the overnight ultracentrifugationpellet, instead of inverting
the tube onto a sterilizing filter [38]– we could no longer
pellet substantial AChE activity in the 2 K pellet of NCM
(“extra-depleted”, Figure 4(d)). In contrast, Jurkat cells
incubated with an extra-depleted medium still appeared
to release AChE, mainly in the 2 K pellet, but also some in
the 100Kpellet. Thus, AChEmay be, in part, secreted from
human T-cells, but is not enriched in sEVs, and bovine
AChE can be a source of AChE detected in exosome- and
sEV-containing pellets. Moreover, when we analysed 2 K,
10 K and 100 K pellets obtained from extra-depleted CCM
by electron microscopy (Figure 4(e–h)), we found that
AChE signal was mainly associated with small, slightly
electrodense structures that seem to be devoid of the lipid
bilayer characteristic of EVs. Some AChE+ vesicles were
found in the 2Kpellets, but vesicles in the 100Kpellet seem
to be mainly negative for AChE, although sometimes with
AChE+ structures sticking to them. In fact, double labelling
of 100 K pellets with anti-AChE and anti-CD63 antibodies
demonstrated that, inmost cases, the two proteinswere not
on the same structures. Structures positive for CD63 are
clearly lipid bilayer vesicles (Figure 4(h)).
Since the non-EV AChE+ structures could be proteins
and other contaminants within vesicle preparations, we
then used size-exclusion chromatography (SEC) as an
additional separation step for 100 K pellets obtained from
Figure 2. Most AChE activity in serum-containing medium is not pelletable. (a) AChE activity was not detected in serum-free media
formulations (AIM Vand RPMI-1640 NCM), but was found at high levels in serum-containing medium (R10 = RPMI 10% FBS NCM).
Differential ultracentrifugation of AIM Vand RPMI recovered no activity in differentially centrifuged pellets (2 K, 10 K, 100 K). From
serum-containing medium, only a very small fraction of total AChE activity could be recovered by differential centrifugation, and
values in complete NCM. (b) After conditioning medium with 72 h culture of PM1 lymphocytic cells, similar amounts of AChE activity
as in (a) could be pelleted from serum-containing medium. Comparatively smaller amounts were recovered when cells were
switched to AIM V medium.
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Figure 3. Compared with particle counts, AChE activity is relatively unaffected by conditioning and centrifugation. (a) Scheme of
experimental workflow. NCM (R10, shown here, or AIM V, See supplement) was conditioned (CCM) by 72 hr culture of H9
lymphocytic cells. 2 K, 10 K, and 100 K supernatant (S/N) and pellet (P) fractions were obtained. AChE activity and particle counts
were measured by activity assay and ZetaView NTA (JHU settings), respectively, for all fractions, and adjusted for total activity (AChE,
miliUnits) or particle counts in the original culture volume. (b) Conditioning of R10 and successive depletion of CCM by
centrifugation resulted in no significant changes in S/N AChE levels (n = 5). (c) Centrifuge pellets corresponding to the depletion
steps in (b) contained only a small amount of total AChE and could not explain minor apparent fluctuations in S/N AChE. (d) Particle
counts for the same experiments showed that particles could be depleted progressively from S/N by differential centrifugation (2 K,
10 K, 100 K), reaching significant differences with the 100 K step despite substantial variability. (e) Particles depleted from S/N were
substantially recovered in the pellets. (f) Per-particle AChE activity is highest in supernatants, not pellets, and is not enriched in
presumed sEV-enriched fractions (representative data of n= 5 experiments). (g) Ratio of per-particle activity of pellets vs
corresponding supernatants: the ratio is significantly higher after the low-speed step (2 K) rather than after the presumably sEV-
enriching high-speed step (100 K). For all panels, data were compared using ANOVA for matched data and with Tukey’s post-test to
correct for multiple comparisons; *: p < 0.05; ***: p < 0.0001. However, for panels B and D, the normalizing group was excluded
from analysis because values were set equal to one. Data are from five independent experiments with three technical (measure-
ment) replicates each.
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Figure 4. Detection of AChE by Western blot in pellets from different Jurkat cell-conditioned medium (CCM) and non-conditioned
medium (NCM). Left panels = representative WB, right panels, quantification of the AChE signals in 3 to 6 independent Western
blots. AU = AChE band intensity in a given pellet/sum (AChE band intensity in all 6 pellets). (a) RPMI with 10% FBS. (b) Serum-free
TexMACSTM medium. (c) RPMI-10% FBS depleted from serum EVs by overnight ultracentrifugation. (d) RPMI-10% FBS extra-depleted
of serum EVs by overnight ultracentrifugation leaving out 5ml above pellet. 2 K, 10 K100 K = pellets recovered from 20ml of CCM or
NCM. AChE is clearly detected in non-conditioned serum-containing medium (a), and is only partially depleted by EV depletion (c).
(e-g) Representative images of immunogold labelling for AChE of 2 K, 10 K and 100 K pellets recovered from conditioned medium
(RPMI-10% extra-depleted of serum EVs). Close-ups of the areas inside white squares are shown. (h) CD63/AChE double stain of 100
k pellets recovered from Jurkat conditioned medium (extra-depleted from FBS).
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extra-depleted CCM. SEC allows vesicle elution in early
fractions (e.g. 7–10 with themethod we used, fractions 1 to
6 corresponding to the void volume of the column), prior
to the bulk of non-vesicular proteins in fractions 13 and
later [39]. We then performed WB, NTA, and AChE
activity measurements for fractions 6 to 14 (Figure 5). We
observed AChE by WB mainly in fractions 13 and 14
(Figure 5(a)), coincident with the strongest AChE activity
in these fractions (Figure 5(b)). However, CD63 and CD81
markers were most enriched in fraction 9 (Figure 5(a)),
which is also the fractions with the highest particle counts
and very low levels of AChE (Figure 5(a,b)).Moreover, EM
confirmed that EV-enriched SEC fractions are almost
devoid of AChE labelling (Figure 5(c)), and that the small
structures positive for AChE observed in CCM before SEC
(Figure 4(e-h)) are strongly decreased in the EV fractions
after SEC. Finally, double labelling with CD63 and AChE
antibodies confirms that sEVs containing CD63 (probably
genuine endosome-derivedexosomes) are devoid of AChE,
which is found in structures with non-vesicular appearance
(Figure 5(d)).
Similar results were obtained by SEC of 100 K pel-
lets obtained from H9 cells cultured in medium sup-
plemented with commercial EV-depleted FBS.
Fractions 8 and 9 were most enriched in CD63 and
CD81 (Figure 5(e)) and had the highest particle counts
(Figure 5(f)), whereas AChE activity was enriched in
fractions 13 and 14 (Figure 5(f)). AChE activity was
below the limit of detection for the EV fractions. In
addition, we used primary human red blood cells
(RBCs) since they are likely to express AChE. RBCs
cultured in medium supplemented with commercial
EV-depleted serum were used to obtain 100 K pellets
that were further separated by SEC. In these condi-
tions, RBCs did not release as many EVs as H9 cells
(Figure 5(f,h)), but did release measurable AChE along
with CD63 in fractions 7–9 (Figure 5(g,h)). However,
the majority of AChE activity was again found in the
non-EV-containing fractions (Figure 5(h)).
AChE activity appears in the least dense and most
particle-depleted velocity gradient fractions
We finally applied iodixanol velocity gradient separa-
tion [40] to determine the level of association of AChE
and AChE activity with vesicle or viral fractions of 100
K pellets from Jurkat cells infected with pseudotyped
HIV-1(NL4-3) and PM1 infected with HIV-1(BaL). For
Jurkat, six fractions were obtained. A representative
image of a Western blot of CD63 (Figure 6(a)) revealed
this tetraspanin in middle and bottom fractions, corre-
sponding to host vesicles and virions, respectively. In
contrast, AChE protein was detected in the top, lightest
fractions (Figure 6(a,b)), and HIV p24 (Figure 6(a,c))
was found in the bottom, heavy fractions. For PM1
CCM, because of availability of different rotors in the
different laboratories, we used another variation of the
gradient protocol [40], with 12 fractions collected.
Tetraspanins CD63, CD81, and CD9 were detected in
both middle and bottom fractions (Figure 7(a)); pre-
sumably sEV-depleted cellular proteins GM130 and
calnexin were strongly depleted or not detected across
fractions (Supplemental Figure 3(a)). Particle counts by
NTA were highest in the bottom, virion-containing
fractions, and also detectable in middle fractions,
whereas AChE activity was predominantly in the top,
light fractions (Figure 7(b,c)). Bottom, heavy fractions
contained most HIV-1 p24 protein as measured by
ELISA and WB (Supplemental Figure 3B, C).
Discussion
Our results suggest that AChE activity is not a univer-
sal marker of mammalian sEVs and cannot be used to
quantitate EVs reliably, except perhaps in specific cell
systems.
This conclusion is based first on a demonstration
that AChE is mainly secreted as a non-vesicle-asso-
ciated form. According to our data, AChE activity
does not correlate with particle count. When ultracen-
trifuged small EV-enriched pellets are further separated
by size-exclusion chromatography and iodixanol gradi-
ent alike, AChE activity is found almost exclusively in
fractions that are particle-poor and depleted of EV
markers. Finally, analysis of EV-enriched pellets by
immuno-EM shows AChE mainly on non-vesicular
structures.
The second reason for not using AChE as a marker of
cell-derived vesicles is the observation that, in cell culture, a
vastmajority of AChE activity associated with standard EV
preparations appears to be derived from serum. With
appropriate dilution and ultracentrifugation, serum can
be depleted of many but not all EVs [36,37,41], yet AChE
activity is inefficiently removed from diluted serum by
centrifugation, suggesting that most serum AChE activity
resides in a soluble fraction and does not associate tightly if
at all with vesicles. Importantly, though, as shown here,
most of the pelletable AChE can be removed by following
an “extra-depletion” process in which a portion ofmedium
closest to the pellet is left behind during harvesting. This
fraction contains AChE associated with loosely pelleted
material. The small percentage of activity that is pelleted
or retained in the volume just above the pellet could be
explained by sedimentation of the large G4 complex of
AChE/BChE, which has a molecular mass of 340,000 kDa
[18,19]. It remains unclear howmuch of the activity in any
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fraction can be attributed to AChE versus BChE, since they
both act on the substrate and can be difficult to distinguish
even with some antibodies [42].
A relatively minute but highly variable amount of
AChE activity could be found in cell-conditioned,
serum-free or extra-depleted medium, and a small
portion of this activity could be pelleted by differential
centrifugation. There was no consistent enrichment of
this activity/protein in 100 K pellets, however, and indeed
we observed a depletion in the PM1 and Jurkat cell
studies, contrary to suggestions that AChE is a marker
of small EVs, specifically exosomes. Furthermore, it is
Figure 5. Separation of EVs from soluble proteins by size-exclusion chromatography. 100 K pellets from (extra-depleted) condi-
tioned medium of Jurkat (a-d), and (commercial EV-depleted FBS) conditioned medium of H9 (e-f) and primary RBCs (g-h) were
passed through a SEC column, and 14 fractions of 0.5 mL were collected. Western blot for CD63, CD81 (a, e, g) and AChE (a) of
fractions 6–14 are shown. (b, f, h) Particle count (NTA) and AChE activity were measured in fractions 6–14 by ZetaView, with settings
and measurement parameters as indicated in Materials and Methods for CT (b) or JHU (f, h) laboratories. (c, d) Representative
overview and higher magnification images of immunogold labelling for AChE alone (c) or in combination with CD63 (d) of 100 K
pellets recovered from Jurkat conditioned medium (extra-depleted from FBS).
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unclear if the measured activity/protein was released by
the cultured cells or was simply residual activity from
serum that had not been adequately washed off when
cells were switched to serum-free medium. This sort of
carryover has been observed previously in RNA studies,
where some serum miRNAs can persist even after wash-
ing and passaging of cells in serum-free medium
[37,43,44]. It is possible, though, that small amounts of
AChE (or BChE) are made by cultured cells. Although
most blood cells, including even primary mature erythro-
cytes and leukocytes, display little AChE activity [22],
AChE mRNA was reported in some immune cell lines
[45]. Considering the disparity between AChE levels in
serum-containing and serum-free conditions, however,
Figure 6. Detection of AChE, EV- and virus-associated proteins in iodixanol velocity gradients of small EVs released by HIV-infected
Jurkat cells. (a) Representative Western Blots showing six fractions recovered from iodixanol gradients of the 100 K pellet of Jurkat
infected with HIV(NL4-3) virus (extra-depleted medium). Viral p24 protein is recovered in the bottom fractions, cellular CD63 in the
middle and bottom fractions, AChE in the top fractions. (b, c) quantification of the AChE and p24 signals in three independent
Western blots. AU = band intensity in agiven pellet/sum (band intensity in all 6 pellets).
Figure 7. AChE activity and particle counts in iodixanol velocity gradients of small EVs released by HIV-infected PM1 and H9 cells.
Twelve fractions were recovered from iodixanol gradients of the 100 K pellet of PM1 cells infected with HIV(BaL) and cultured in
commercial EV-depleted FBS medium. (a) Western blot of CD63, CD81, and CD9 in fractions 1–12 (from the experiment also
depicted in panel c). (b, c) Particle counts (NTA by ZetaView, with settings and measurement parameters as specified in Materials
and Methods for the JHU lab) and AChE activity of two cultures of PM1 cells: values are expressed per mL of final washed and
resuspended fraction (1 mL each). Only those points marked by “*” were above the limit of quantitation of the AChE assay (fractions
2–4). Data shown in panels b and c are from 2 independent experiments (with 3 or more technical replicates each).
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production of AChE by cells in culture may need to be re-
evaluated in serum-free culture conditions following
careful removal of residual serum components.
How did AChE evolve from a marker of RBC EVs,
as developed in the 1970s, to a putative general EV
marker? More recent literature seems to reference the
initial RBC studies, attributing AChE not as an RBC
EV marker, but rather as a generic EV or exosome
marker [32–34,46–48]. These later investigations do
not appear to have involved RBCs or related cells
directly, nor was a rationale provided for the use of
AChE as an EV/exosome surrogate. Such applications
of AChE have included cancer immunology research
[31] and HIV studies in immune cells such as primary
human mononuclear leukocytes and leukemic B- and
T-cell lines [32–34,46,49]. Some of these studies used
AChE activity as a negative marker for HIV virions,
separated from presumably AChE-harbouring exo-
somes by density gradient [32,33,48]. This new appli-
cation of AChE activity may have arisen from an
historical misreading of the reticulocyte literature
(which we have not pinpointed) followed by uncritical
citation. Indeed, our findings confirm that AChE is
strongly associated with neither HIV virions nor host
EVs in common HIV experimental systems.
Our findings show that AChE is not a universal marker
of EVs; however, it is possible that it could be useful for
some cell types (such as neurons or reticulocytes) or in
some biological fluids. It is worth noting that in the RBC
cultures used here, only about 2% of the cells correspond to
reticulocytes, which release abundant EVs when maturing
to erythrocytes. Therefore, the low level of AChE detected
in EVs probably comes from the few reticulocyte-derived
EVs, whereas abundant AChE detected predominantly in
non-EV fractions may come from the culture medium or
residual plasma. For these reasons, researchers who pro-
pose AChE as an EV or exosome marker would be well
advised to consider experiments in their specific system(s)
to establish that AChE/AChE activity is:
● highly expressed and membrane-associated in the
cell of interest;
● released predominantly in physical association
with EVs (and with presumed late endosomal
markers if exosome-association is claimed), and
not (or to a lesser extent) in non-EV fractions;
and
● not an exogenous artifact (through use of serum-
free culture conditions).
Without these steps, the specificity and sensitivity of
AChE as an EV or sEV/exosome marker may remain
in doubt.
Methods
Cell lines, red blood cells, and HIV-1 strains
Cell lines used in this study included: in KWW lab, U937
(ATCC #CRL-1593.2), H9 (ATCC #HTB-176), PM1
(AIDS Reagent Program, Cat #: 3038); in CT lab, Jurkat
cells (identified by short tandem repeat profiling as similar
to J77 clone 20). Red blood cells (about 98% erythrocytes
and less than 2% reticulocytes) were obtained from blood
donated by a healthy, consenting individual per Protocol
NA_00093758 approved by the Institutional Review Board
of the JohnsHopkinsUniversity School ofMedicine. Blood
was centrifuged within 20 min of collection through Ficoll
at 400 x g for 15 min and the bottom fraction correspond-
ing to RBCs was collected (KWW lab). HIV-1 strains were
NL4-3 (CT lab), BaL and Rf (KWW lab). To prepare
pseudotyped virus (in CT lab), HEK-293T cells were cul-
tured inDMEM-GlutamaxTM supplementedwith 10%FBS
(Gibco) and Penicillin-Streptomycin (Gibco). VSV-G-
pseudotyped viral particles were produced by transfection
of HEK-293T with a mixture of pBR-NL43-IRES-eGFP-
Nef+ (NL4-3-IRES-eGFP, encoding full-length HIV-1 in
the pBR322 backbone under the control of viral long term-
inal repeat promoter, generated by Dr. F. Kirchhoff
[Institute of Molecular Virology, Ulm University Medical
Center, Ulm, Germany [50]] and pCMV-VSV-G using
TransIT-293 reagent (Mirus Bio), following the manufac-
turer’s recommendations. Virus-containing cell superna-
tants were recovered after 72 h, filtered at 0.45 μM,
aliquoted and stored at −80°C. Jurkat cells were infected
with VSV-G–pseudotyped NL4-3-IRES-EGFP-Nef+ virus
(20–50 ng p24/ml) for 2 h before beingwashed 3 timeswith
PBS and incubated with the different media for EV isola-
tion. In KWW lab, chronically HIV-BaL-infected PM1
cells were cultured in 10% FBS containing RPMI-1640
medium until cell density reached 1.2 – 1.5 × 106 cells/
mL. Virus-containing CCM were harvested by pelleting
cells at 1,500 rpm for 5 min. The supernatant was pelleted
twice to remove cell debris and large vesicles (2,000 x g for
20min each) and then at 10,000 x g for 40 min. Finally, the
supernatant was centrifuged at 100,000 x g for 90 min (as
below for EVs). The virus pellet was resuspended in 1xPBS
and aliquoted and stored at-80°C until use.
Cell culture
Cells were cultured in RPMI-1640-GlutamaxTM med-
ium (Gibco) with Penicillin-Streptomycin (Gibco) and
10% FBS (Gibco, batch 42F2567K) for Jurkat cells (CT
lab), or RPMI-1640 (Gibco) supplemented with 10%
FBS (HyClone SH30396.03, Lot AC11258322) for H9
and PM1 cell culture (KWW lab); KWW lab also used
commercial depleted FBS in Figures 5 and 7: GIBCO
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Exosome-Depleted FBS, A27208-01, Lot 1,838,765. All
sera were heat inactivated at 56°C for 30 min. For
serum-free culture, KWW lab used AIM V(Gibco),
and CT lab used TexMACSTM (Miltenyi Biotec)
media, as indicated. Cells were cultured at an initial
density of approximately 0.5 to 1 × 106 cells/ml in the
indicated medium for 48 to 72 h, as indicated, prior to
the harvest of CCM. Equal volumes of medium without
cells were used to obtain cell-free EVs.
In-house preparation of EV-depleted and EV-extra-
depleted medium
EV-depleted and extra-depleted medium were obtained
by overnight ultracentrifugation at 100,000 × g in a
Type 45 Ti rotor (Beckman Coulter, k-factor 1042.2) of
RPMI-1640 medium (Gibco) supplemented with 20%
FBS (Gibco, batch 42F2567K). After centrifugation,
EV-depleted medium was defined as the supernatant,
whereas EV-extra-depleted medium was defined as the
EV-depleted supernatant when carefully pipetted from
the top and leaving 5 ml in the bottom of each tube to
avoid disturbing bottom layers or the pellet.
Supernatants were filtered through a 0.22 μm bottle
filter (Millipore), and additional RPMI medium and
antibiotics were added to prepare complete medium
(10% EV-depleted FBS final).
EV separation from CCM and NCM
EVs were separated by differential ultracentrifugation
as previously described [36]. Briefly, conditioned med-
ium was centrifuged at 300 × g for 20 min at 4°C to
pellet cells. Supernatant was centrifuged at 2,000 × g
for 20 min at 4°C (2 K pellet), transferred to new tubes,
and centrifuged in a Type 45 Ti rotor (Beckman) for 35
min at 10,000 × g (9,000 rpm = 10 K pellet, k-factor
3473.6), and finally for 90 min at 100,000 × g (30,000
rpm = 100 K pellet, k-factor 1042.2) (CT lab).
Alternatively (KWW lab), an AH-629 rotor (Sorvall)
was used for the 10 K(change: 40 min) and 100 K steps.
All pellets were washed in 50–60 mL of PBS and
recentrifuged at the corresponding speed before being
resuspended in sterile PBS. Cells recovered from the
300 × g pellet were counted by Countess (Invitrogen).
Viability was assessed by Trypan Blue stain 0.4% (Life
Technologies) exclusion.
Size-exclusion chromatography (SEC) separation
500 microliter samples containing 100 K pellets iso-
lated from 180 million cells (Jurkat), or approximately
200 million H9 cells or RBCs were overlaid on 70 nm
qEV size-exclusion columns (Izon, SP1) followed by
elution with PBS in 500 μl fractions according to the
manufacturers’ instructions. Fractions 6 to 14 were
collected and analysed directly by WB (12 μl), NTA
(10 μl), and for AChE activity (50 μl).
Iodixanol gradient separation
100 K pellets obtained by ultracentrifugation of condi-
tioned medium from approximately 60 million cells
(Jurkat NL4-3-IRES-EGFP-Nef+-infected or PM1
BaL-infected) were resuspended in 1 ml of PBS and
layered on top of iodixanol (OptiprepTM, Sigma-
Aldrich #D1556) gradients. Gradients were prepared
in PBS in 4% increments ranging from 6 to 18%
(Jurkat) or in 1.2% increments ranging from 6 to 18%
(PM1) and centrifuged for 1 h at 4°C at 200,000 × g
(35,000 rpm) in a SW 41 Ti rotor (Beckman Coulter),
stopping without brake (Jurkat), or for 2 hat 4°C at
210,000 × g in a TH-641 rotor (Sorvall, for PM1). After
centrifugation, six fractions of 2 ml (Jurkat) or 12
fractions of 1 ml (PM1) were collected from the top
of the tube. The fractions were then diluted to 35 ml
with PBS to be washed by ultracentrifugation for 40
min at 100,000 × g (25,000 rpm) in a SW 32 Ti rotor
(Beckman, Jurkat cells) or AH-629 rotor (Sorvall, PM1
cells). The fractions were resuspended in 15 μl of PBS
and used for WB analysis.
Western blotting
Vesicles recovered from conditioned medium from 20
× 106 cells (2 K, 10 K and 100 K pellets), equivalent
volumes of cell-free medium (2 K, 10 K and 100 K
pellets) or 15 μl of the iodixanol gradient fractions were
loaded on 4–15% or 10% Mini-Protean® TGX Stain-
Free™ gels (Bio-Rad), under non-reducing conditions.
Transferred membranes (Immun-Blot PVDF Bio-Rad)
were developed (e.g. using Clarity western ECL sub-
strate (Bio-Rad) or SuperSignal West Pico Plus
Chemiluminescent Substrate (Thermo Fisher) and a
ChemiDoc Touch imager (Bio-Rad) or by standard
film exposure). Intensity of the bands was quantified
using ImageLab Software (Bio-Rad). Antibodies for
WB were mouse anti-human CD63 (clone H5C6, BD
Bioscience #557305), mouse anti-human CD81 (Santa
Cruz sc-23692), goat anti-AChE (ab31276, Abcam) and
anti-HIV-1 p24 Monoclonal (183-H12-5C, NIH AIDS
reagent program) or Anti-HIV1 p55 + p24 + p17
(ab63917, Abcam). Secondary antibodies included
HRP-conjugated goat anti-rabbit IgG (Santa Cruz, sc-
2004) and HRP-conjugated m-IgG-k BP (Santa Cruz,
sc-516102) (JHU), or (CT lab) HRP-conjugated anti-
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mouse (Jackson Immunoresearch, 115–035-146) and
anti-goat (Jackson, 705–035-147).
HIV p24 ELISA
Anti-HIV p24 ELISA Kit (NEK 050) was purchased
from PerkinElmer, Boston, MA, and manufacturer’s
protocol was followed.
Acetylcholinesterase activity measurements
AChE activity was determined by colorimetry using the
Acetylcholinesterase Assay Kit (Abcam ab138871)
including a standard curve. Manufacturer’s protocol
was followed throughout. Absorbance was measured
with a Bio-Rad iMark Microplate Reader (KWW
laboratory) or a Spark-Stack TECAN Microplate reader
(CT laboratory).
Nanoparticle tracking analysis
NTA was performed by NanoSight NS300 or NS500
(Malvern Instruments) or ZetaView (Particle Metrix).
Dilutions: where possible, for NanoSight, samples were
diluted to read in the range of 1–10 E 8 particles/mL, and
for ZetaView, fromapproximately 1.5 – 50E 7particles/mL
(note that these concentrations mostly represent particles
ranging from 90 to 200 nm in diameter). For NanoSight, at
least five 20-s videos were recorded for each sample at a
camera setting of 11 or 12, as specified in the figure legends.
Data were analysed at a detection threshold of 5 using
NanoSight software version 3.1. For ZetaView, the
ZetaViewPMX-120 (ParticleMetrix)with software version
8.04.02 was used in both laboratories. At JHU, the instru-
ment was set at 25°C, sensitivity of 80, and shutter at 100,
with a frame rate of 30 frames per second. In theCT lab, the
instrument was set at 22°C, sensitivity of 70 and shutter of
75. Measurements were done at 11 different positions (5
cycles per position) and frame rate of 30 frames per second.
Summary data for all measurements are available upon
request.
Electron microscopy
Electron microscopy was performed on pellets stored at
−80°C that had never been thawed and re-frozen. EV
suspension in PBS was deposited on formvar/carbon–
coated copper/palladium grids before uranyl/acetate con-
trasting andmethyl-cellulose embedding for whole-mount
analysis as described previously [51]. In case of AChE
immunostaining, samples on grids were successively incu-
bated with anti-AchE (ab31276, Abcam, 2.5 µg/ml in PBS-
BSA 1% for 30 min), rabbit anti-goat (Sigma SAB3700272,
5 µg/ml in PBS-BSA 1% for 30min), and 10 nmprotein-A-
gold (CMC, Utrecht, The Netherlands, 1:50 dilution in
PBS-BSA 1% for 20 min) before fixation. Double immu-
nostaining was performed by successively incubating with
goat anti-AChE (ab31276, Abcam), rabbit anti-goat (Sigma
SAB3700272), and 15 nm protein-A-gold (CMC, Utrecht,
The Netherlands), 1% glutaraldehyde (Electron
Microscopy Sciences, for 5 min), followed by anti-CD63
(857.770.000 TS63 Diaclone, 20 µg/ml in PBS-BSA 1% for
30 min), anti-mouse IgG-10-nm protein-A-gold (Aurion,
diluted 1:10 in PBS-BSA for 30 min), and fixed for 5 min
with 1% (w/v) glutaraldehyde in PBS. Subsequently, after a
wash on 10 droplets of distilled water, grids were trans-
ferred to droplets of 0.4% (w/v) uranyl acetate (UA) stain-
ing and 1.8% (w/v) methyl cellulose (MC) embedding
solution. After 10 min of incubation, grids were picked
up in a wire loop. Most of the excess of the viscous embed-
ding solution was drained away with filter paper after
which the grids with sections were air-dried forming a
thin layer of embedding solution. Images were acquired
with a digital camera Quemesa (EMSIS GmbH, Münster,
Germany) mounted on a Tecnai Spirit transmission elec-
tron microscope (FEI Company) operated at 80 kV.
Statistical methods and data representation
We generally follow recent recommendations regarding
transparency in data representation [52,53] by plotting
independent data points for experiments with four or
fewer points so that readers may “interpret the data for
themselves, rather than showing possibly misleading P
values or error bars and drawing statistical inferences”
[52]. Where statistical tests have been applied (e.g. Figure
3, with five independent experiments), ANOVA was done
followed by Tukey’s post-test.
EV-TRACK submission
We have submitted relevant data of our experiments to
the EV-TRACK knowledgebase (EV-TRACK ID:
EV180030) [54].
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